Suppr超能文献

外用0.8%吡罗昔康和50+防晒滤光剂对接受或未接受光敏性利尿药治疗的高血压患者光化性角化病的影响:一项观察性队列研究。

Effects of topical 0.8% piroxicam and 50+ sunscreen filters on actinic keratosis in hypertensive patients treated with or without photosensitizing diuretic drugs: an observational cohort study.

作者信息

Mazzilli Sara, Garofalo Virginia, Ventura Alessandra, Diluvio Laura, Milani Massimo, Bianchi Luca, Campione Elena

机构信息

Department of Dermatology, University of Rome "Tor Vergata", Rome, Italy.

Medical Department, Cantabria Labs Difa Cooper, Caronno Pertusella, Italy,

出版信息

Clin Cosmet Investig Dermatol. 2018 Oct 12;11:485-490. doi: 10.2147/CCID.S178386. eCollection 2018.

Abstract

BACKGROUND

Photosensitizing diuretics use (especially thiazide compounds) is associated with a significantly higher risk of squamous cell carcinoma (SCC). Actinic keratosis (AK) is a precursor of SCC.

STUDY AIM

To evaluate in a prospective cohort study the efficacy of topical piroxicam 0.8% and sunscreen 50+ (ACTX) in the treatment of AK in hypertensive subjects with or without TD treatment.

SUBJECTS AND METHODS

A total of 119 hypertensive subjects with multiple AK (39 under chronic TD treatment; and 80 treated with other non-TD, non-photosensitizing antihypertensive drugs) were enrolled after their informed consent in a 6-month observational cohort study. All the subjects were treated with ACTX twice daily. The primary endpoint was the evolution of AK lesions at baseline, after 3 and 6 months. The secondary endpoint was the clearance of AK target lesions and field of cancerization by dermoscopic evaluation using a score evaluating erythema, scaling, pigmentation, and follicular plugs (ESPFP score; ranging from 0 to 20). An investigator, unaware of the type of antihypertensive treatments (TD or non-TD), performed all the clinical and dermoscopy evaluations.

RESULTS

At baseline, AK mean (SD) lesion number in TD group was 14.1(4) and 14.6(4) in the non-TD group. ESPFP mean (SD) score at baseline was 5.8(1.2) in both groups. A significant reduction of AK lesions in comparison with baseline was observed in both groups. A statistically significant greater reduction was observed in TD in comparison with the non-TD group (-54% vs -32%). ESPFP score was reduced in a higher proportion in the TD group in comparison with the non-TD group (-60% vs -37%, respectively). ACTX treatment was very well tolerated.

CONCLUSION

In hypertensive subjects with multiple AK, the topical use of ACTX is associated with a significant reduction of lesions count with an improvement in the field cancerization. The clinical efficacy is more pronounced in subjects under thiazide diuretics treatment.

摘要

背景

使用光敏性利尿剂(尤其是噻嗪类化合物)与鳞状细胞癌(SCC)的风险显著升高相关。光化性角化病(AK)是SCC的前驱病变。

研究目的

在一项前瞻性队列研究中,评估0.8%的外用吡罗昔康和50+防晒霜(ACTX)对接受或未接受噻嗪类利尿剂(TD)治疗的高血压患者AK的治疗效果。

受试者与方法

119例患有多发性AK的高血压患者(39例接受慢性TD治疗;80例接受其他非TD、非光敏性抗高血压药物治疗)在签署知情同意书后纳入一项为期6个月的观察性队列研究。所有受试者每天使用ACTX两次。主要终点是基线、3个月和6个月后AK病变的变化情况。次要终点是通过使用评估红斑、鳞屑、色素沉着和毛囊栓的评分(ESPFP评分;范围为0至20)进行皮肤镜评估,使AK靶病变和癌变区域清除。一名不了解抗高血压治疗类型(TD或非TD)的研究者进行了所有临床和皮肤镜评估。

结果

基线时,TD组AK病变的平均(标准差)数量为14.1(4),非TD组为14.6(4)。两组基线时ESPFP平均(标准差)评分为5.8(1.2)。两组与基线相比,AK病变均显著减少。与非TD组相比,TD组观察到统计学上显著更大程度的减少(-54%对-32%)。与非TD组相比,TD组ESPFP评分降低的比例更高(分别为-60%对-37%)。ACTX治疗耐受性良好。

结论

在患有多发性AK的高血压患者中,外用ACTX与病变数量显著减少及癌变区域改善相关。在接受噻嗪类利尿剂治疗的患者中,临床疗效更为显著。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c654/6188002/dd32a005b5a8/ccid-11-485Fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验